The pioneering service, developed under the clinical leadership of Professor Geoffrey Hackett, one of Europe’s top sexual medicine experts, marks an important moment in women’s healthcare – making evidence-based treatment accessible through digital consultations where traditional healthcare has failed to act.
Despite affecting 43 percent of women compared to 31 percent of men, female sexual dysfunction (FSD) receives a fraction of the research funding and treatment options available for male erectile dysfunction. Women undergoing menopause and those with diabetes are particularly susceptible to experiencing FSD. Healthcare systems have historically focused on reproductive rather than pleasure based sexual health, with a lack of female representation in sexual health research and drug development.
“The medical establishment, and the British one in particular, has ignored women’s sexual health for decades and prioritised funding the research and development of male treatments,” said Professor Hackett, Evaro’s clinical lead and Professor of Sexual Medicine at Aston University. “We have robust clinical evidence that low-dose daily tadalafil can transform women’s sexual wellbeing – but institutional inertia has always blocked access. Evaro’s digital infrastructure finally breaks down these barriers, delivering treatment that should have been available years ago.”
The service provides comprehensive online consultations, expert clinical oversight, and treatment using medication usually prescribed for erectile dysfunction, but shown to work for orgasmic dysfunction for a large percentage of women . Other potential medical treatments include low dose testosterone, for those women that struggle with sexual desire. Through data-driven safety monitoring and access to patients medical history, Evaro will ensure the highest standards of patient care and safety. Evaro’s platform also provides ongoing support as well as educational resources addressing the sexual health information gap to deliver a comprehensive treatment service for female sexual dysfunction.
Dr Oskar Wenbar, COO and co-founder of Evaro, said: “While men have had Viagra since 1998, women with sexual dysfunction are often being told it’s ‘all in their head’ or offered antidepressants. They’re forced to choose between suffering in silence or battling a healthcare system that treats female pleasure as either irrelevant or embarrassing. By combining Professor Hackett’s world-leading expertise with our digital infrastructure that already serves 750,000 patients, we’re hoping to help fix this imbalance. Women deserve the same rapid access to evidence-based sexual health treatments that transformed many men’s lives years ago.”
The service will generate real-world evidence on treatment of FSD in women, potentially informing future clinical trials and treatment protocols. Research shows that addressing sexual dysfunction can significantly reduce anxiety and depression related to these conditions, improving overall mental health and quality of life.
The service is available immediately through Evaros most prominent B2C brand, e-surgery.com. The company plans to extend access through other partners, making the treatment accessible to millions of affected women across the UK.






